The antibiotic vancomycin blocks the construction of bacterial cell walls.

This structure includes vancomycin (blue) and a short analogue of a bacterial peptidoglycan chain (red).
Download high quality TIFF image
Much of our current arsenal of antibiotics is borrowed from the world's true experts in infection control: bacteria and fungi. These organisms protect themselves with a bewildering collection of exotic chemical weapons, evolved to attack weak points in their competitors. Many of these antibiotic compounds, such as penicillin, attack enzymes, blocking their action and ultimately killing the infecting bacterium. Vancomycin, on the other hand, attacks the thing being build by a bacterial enzyme.

Blocking Construction

Bacteria build a sturdy cell wall composed of sugar chains crosslinked by short peptides, forming a network called peptidoglycan. This network is built in many steps, laying down the sugar chains and building the peptide connectors. Vancomycin acts near the end of this process. One end of the crosslinking peptide has two alanine amino acids (more specifically, D-alanines, with stereochemistry opposite from the normal L-alanines). To form the crosslink, the final alanine is popped off, and the peptide is attached to a neighboring peptide. As shown here in PDB entry 1fvm , vancomycin binds tightly to this D-alanine-D-alanine peptide, blocking the ability to form the crosslink.

Positive and Negative

Only some bacteria are susceptible to vancomycin. Bacteria such as Staphylococcus have a thick layer of peptidoglycan that surrounds the cell, and are termed gram positive because of the way this peptidoglycan takes up crystal violet stain when observed in the microscope. Vancomycin is effective for blocking formation of this type of cell wall and is currently used as a last resort antibiotic for persistent infections by these bacteria. Gram negative bacteria such as Escherichia coli, on the other hand, build their peptidoglycan beneath an outer membrane, where it is protected from this stain and from attack by vancomycin. So, smaller antibiotics like penicillin are needed to get inside in these bacteria.

VanA reconstructed from a 30,000 year old bacterium, with bound ATP in red.
Download high quality TIFF image

Ancient Resistance

Bacteria become resistant to vancomycin by getting rid of its target. The protein VanA, with the help of two other proteins, adds a lactate group instead of alanine to the end of the peptidoglycan chain. This works just as well for the crosslinking, but is not susceptible to the antibiotic. The structure shown here is VanA from an ancient bacterium, recreated from DNA from 30,000 year old permafrost sediments (PDB entry 3se7 ). Surprisingly, it is very similar to VanA made by modern bacteria, showing that this war of antibiotics and resistance began long before medical science discovered the utility of antibiotics. You can compare the ancient and modern proteins using the Structure Comparison Tool.

Exploring the Structure

VanA and D-alanine-D-alanine Ligase (PDB entries 1e4e and 2dln)

We can learn about the evolution of VanA by looking at other bacterial proteins. VanA is a D-alanine-D-lactate ligase, indicating that it adds lactate to the growing peptidoglycan chain. The enzyme that makes the normal peptidoglycan is a D-alanine-D-alanine ligase, which adds alanine to the chain. Comparing the two structures, from PDB entries 1e4e and 2dln , shows that they are quite similar, providing evidence that the enzyme providing resistance evolved from the normal enzyme. To explore these two structures in more detail, click on the image for an interactive JSmol.

Topics for Further Discussion

  1. You can explore a variety of similar antibiotics and the enzymes involved in synthesizing them by searching for "glycopeptide antibiotics."
  2. You can look at the VanX protein in PDB entry 1r44, which is also needed for resistance against vancomycin. It is a small enzyme that breaks down any D-alanine-D-alanine peptides that may be present in the cell wall, making room for VanA to build its modified peptides.


  1. 3se7: V. M. D'Costa, C. E. King, L. Kalan, M. Morar, W. W. L. Sung, C. Schwarz, D. Froese, G. Zazula, F. Calmels, R. Debruyne, G. B. Golding, H. N. Poinar & G. D. Wright (2011) Antibiotic resistance is ancient. Nature 477, 457-461.
  2. 1fvm: Y. Nitanai, T. Kikuchi, K. Kakoi, S. Hanamaki, I. Fujisawa & K. Aoki (2009) Crystal structures of the complexes between vancomycin and cell-wall precursor analogs. Journal of Molecular Biology 385, 1422-1432.
  3. 1e4e: D. I. Roper, T. Huyton, A. Vagin & G. Dodson (2000) The molecular basis of vancomycin resistance in clinically relevant Enterococci: crystal structure of D-alanyl-D-lactate ligase (VanA). Proceedings of the National Academy of Sciences USA 97, 8921-8925.
  4. 2dln: C. Fan, P. C. Moews, C. T. Walsh & J. R. Knox (1994) Vancomycin resistance: structure of D-alanine:D-alanine ligase at 2.3 A resolution. Science 266, 439-443.
  5. J. C. J. Barna & D. H. Williams (1984) The structure and mode of action of glycopeptide antibiotics of the vancomycin group. Annual Reviews of Microbiology 38, 339-357.

December 2015, David Goodsell

About Molecule of the Month
The RCSB PDB Molecule of the Month by David S. Goodsell (The Scripps Research Institute and the RCSB PDB) presents short accounts on selected molecules from the Protein Data Bank. Each installment includes an introduction to the structure and function of the molecule, a discussion of the relevance of the molecule to human health and welfare, and suggestions for how visitors might view these structures and access further details. More